Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This pilot study suggests that high-dose testosterone plus finasteride improved knee extensor strength and muscle size in men with impaired gait after chronic incomplete spinal cord injury.

In this case report, the authors described how a 27-year-old male developed scarring and penile shortening after a previous lengthening procedure, which was successfully repaired using a pedicled superficial circumflex iliac artery perforator flap combined with a novel hybrid technique.

This study indicates that the normal human prostate is not a major contributor to circulating blood DHT concentrations in androgen-deficient patients receiving testosterone replacement therapy.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

Finasteride use may be linked to rare testicular tumor, but more research needed.

Large prostate patients more likely to have hair loss.

This discussion highlights the use of minimal incision extraction for lipoma removal, noting that it is a favored technique among dermatologists due to its efficiency, despite some hesitance with larger lipomas.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This study found that nuclear androgen receptor expression was enhanced by dihydrotestosterone in rat gubernacular mesenchyme, but this did not affect muscle morphology or matrix composition during fetal development.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

Finasteride may cause breast enlargement, low testosterone a risk factor.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This study found that Epristeride and Finasteride reduced prostate development and testis weight in male rats, but only Finasteride appeared to impact reproductive function.

This study discusses a hypothesis that combining intermittent androgen ablation therapy with finasteride may enhance prostate cancer treatment, though new results from this approach are not yet available.

This article discusses developments in clinical urology featured in the Journal of Urology's October 1999 issue and presents no new clinical findings.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study found that early treatment with estradiol or dihydrotestosterone significantly reduced prostate adenocarcinoma development in Lobund-Wistar rats, while later treatments were ineffective.

CEC levels may be a useful marker for predicting prostate cancer progression.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.